Mizuho raised the firm’s price target on Evolus to $23 from $20 and keeps a Buy rating on the shares following the Q4 report. The firm now include sales estimates for Estyme and has greater confidence in Evolysse’s competitive profile given data from the Europe head-to-head trial.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EOLS:
- EOLS Upcoming Earnings Report: What to Expect?
- Evolus upgraded to Overweight from Equal Weight at Barclays
- Evolus Stock (NASDAQ:EOLS) Spikes; Analysts See Significant Upside
- Evolus sees FY24 revenue $255M-$265M, consensus $253.27M
- Evolus sees Q4 revenue $61M, consensus $56.97M
Questions or Comments about the article? Write to editor@tipranks.com